EL

Elevance Health, Inc.

ELVHealthcareNASDAQ

Healthcare Plans

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$199.13B
+12.6% YoY
Net Income
$5.66B
-5.3% YoY
Free Cash Flow
$4.31B

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 MACD Positive CrossoverHistogram +0.5307, positive momentum
Sep 2 MACD Positive CrossoverHistogram +0.1553, positive momentum
About Elevance Health, Inc.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The $88.37B market capitalization puts ELV squarely in large-cap range for its industry. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

Where ELV stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, ELV finished 12.56% above its 150-day moving average ($360.56) and 13.83% above its 200-day moving average ($356.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is ELV overbought or oversold?

At the September 3, 2026 close, ELV's RSI(14) was 56.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$88.37B
P/E (TTM)18.02
Fwd P/E13.76
EPS$22.61
Beta0.70
52W Change+32.3%
Dividend Yield1.66%
ROE11.1%
Analysis

Elevance Health, Inc. holds $37.51B in cash against $31.04B in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $4.31B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 11.1%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $156.59B (2022) to $199.12B (2025), reflecting a 27% increase over the period.

ELV's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing ELV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms